HTB July 2022 (1 July 2022) now online

Since 16 May when the initial seven cases had been reported, numbers have approximately doubled every week and by 1 July more than 1075 people have been diagnosed. Globally, there are now more than 4000 cases in 35 countries where MPX is not endemic.

i-Base calls for emergency funding to enable services to adequately respond to the demand for service to cover diagnosis, treatment, management, prevention and information.

And we include two recent Q&A to the i-Base information service with information about taking a four-week break from sex. Or at least sex linked to settings where contact with multiple partners is easy and routine.

But the issue includes lots more:

• Reports from the NAMSAL study at CROI 2022
• EU decision to approve lenacapavir to treat MDR HIV – giving priority access to this first in class capsid inhibitor to those with fewest current options.
• Promising results using bNAbs to suppress HIV off-ART in adults.
• Early date supporting the use of dual bNAbs in children.
• Full results from ANCHOR study published in NEJM
• Early news of a potential vaccine against gonorrhoea.
• Review of a study reporting a potential association of cardiovascular events with integrase inhibitors – though based on a single observational study.

We also include several reports on the developments from COVID-19 as the UK enter the early stage of a new wave with BA.4 and BA.5 omicron variants. Two other articles look at vaccine responses in people living with HIV. And reports from the BMJ report on how the government failed to protect doctors from COVID-19.

Plus how tracking PrEP adherence using sensors in the meds and optimistic new that UK funding for UNAIDS has increased this year, though it is still much lower than before last year’s cuts.

So, although the July issue of HTB is usually slim in expectation of the upcoming IAS conference and related workshops that are held at the end of this month, we think there is still plenty to read.